See All AI Raises $33 Million to Bring Revolutionary AI-Based Sliceable Intraoperative 3D Visualization and Advanced Navigation to Global Healthcare
Summary
These models, sliceable in 1mm increments, enable real-time surgical planning and visualization with fidelity comparable to CT, but without the associated radiation burden, significant costs, or capital footprint.The platform is designed for minimally invasive surgery (MIS) workflows and requires no direct line-of-sight between the companys proprietary visible light camera and the patients anatomy. The system has been designed to be fully compatible with standard surgical draping, shielding, and positioning and integrates into existing operating room environments without disrupting surgeon techniques or workflow.Unlike other technologies that rely on expensive hardware or closed ecosystems, weve taken an open, revolutionary, software-based approach to imaging, said Eric Major, Chief Executive Officer, See All AI. With this funding secured, the platforms design concept validated, and having received notices of allowable subject matter in our first three foundational U.S. patents, See All AI is positioned to lead a new category in surgical imaging.The Companys technologies are not yet FDA-cleared and are not currently available for clinical use. Regulatory submission for FDA clearance is planned in 2025.About See All AISee All AI is a next-generation medical technology company transforming intraoperative 3D imaging and navigation through artificial intelligence, deep learning, and machine vision. Its platform creates detailed 3D models from as few as two intraoperative fluoroscopic images and enables real-time tracking without line-of-sight requirements, expensive hardware, or workflow disruption.